Record-Breaking Price Movement
On 07 Jul 2026, Granules India Ltd’s stock price surged to an intraday high of Rs.872, setting a fresh 52-week and all-time peak. This milestone reflects a 2.21% gain on the day, significantly outperforming the Sensex, which recorded a modest 0.09% rise. The stock has demonstrated strong momentum, gaining for four consecutive days and delivering a cumulative return of 7.24% during this period. Notably, the stock outperformed its sector by 1.85% on the day, highlighting its relative strength within the Pharmaceuticals & Biotechnology industry.
The stock’s volatility was elevated, with an intraday weighted average volatility of 13.05%, indicating active trading interest and dynamic price movements. Granules India is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, reinforcing the bullish technical trend that has been in place since early April 2026.
Long-Term Market Outperformance
Granules India Ltd has delivered exceptional returns over multiple time horizons, significantly outpacing benchmark indices. Over the past year, the stock has appreciated by 77.03%, compared to a decline of 6.10% in the Sensex. Year-to-date, the stock has gained 45.90%, while the Sensex has fallen by 8.06%. The company’s three-year return stands at an impressive 179.90%, dwarfing the Sensex’s 20.03% gain, and its five-year return of 154.79% far exceeds the Sensex’s 47.69% rise. Over a decade, Granules India has delivered a remarkable 510.27% return, more than doubling the Sensex’s 188.05% growth.
Financial Strength and Operational Highlights
Granules India’s recent quarterly results for March 2026 underscore the company’s strong financial position. Net sales reached a record ₹1,470.61 crores, the highest quarterly figure to date. Operating profit to interest coverage ratio also hit a peak of 10.77 times, reflecting the company’s robust ability to service its debt obligations. Cash and cash equivalents at the half-year mark stood at ₹949.06 crores, the highest recorded level, further bolstering the company’s liquidity profile.
The company maintains a low debt-to-EBITDA ratio of 1.28 times, indicative of prudent leverage management. Its debt-equity ratio at half-year was a conservative 0.30 times. These metrics contribute to Granules India’s strong balance sheet and financial resilience.
Quality and Efficiency Metrics
Granules India Ltd is rated as a ‘Buy’ by MarketsMOJO, with a Mojo Score of 72.0, upgraded from a previous ‘Hold’ rating on 06 Apr 2026. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector. Its management efficiency is reflected in a high return on capital employed (ROCE) of 16.82%, signalling effective utilisation of capital resources.
Institutional investors hold a significant 33.61% stake in the company, having increased their holdings by 1.29% over the previous quarter. This level of institutional participation often indicates confidence in the company’s fundamentals and governance standards.
Valuation and Dividend Profile
Granules India’s valuation multiples as of 07 Jul 2026 include a price-to-earnings (P/E) ratio of 35x and a price-to-book value (P/BV) of 4.14x. The enterprise value to EBITDA stands at 18.25x, while the EV to capital employed ratio is 3.83x. The company’s PEG ratio is 1.49x, reflecting the relationship between its price-to-earnings ratio and earnings growth rate.
The dividend yield is modest at 0.17%, with the latest dividend declared at Rs.1.5 per share and a payout ratio of 7.25%. The ex-dividend date is scheduled for 31 Jul 2025.
Technical Analysis and Market Sentiment
The overall technical trend for Granules India Ltd is bullish, a status that has been in place since 06 Apr 2026 when the stock was trading at ₹643.80. Key technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory all signal bullish momentum on both weekly and monthly timeframes. The stock’s immediate support level is at ₹433.00, corresponding to its 52-week low, while the major resistance level is near the 52-week high of ₹874.55.
Delivery volumes have shown an upward trend, with a 1-month delivery change of 10.66% and a 1-day delivery change of 8.98% compared to the 5-day average, indicating increased investor participation in recent trading sessions.
Growth and Quality Assessment
Granules India is recognised as a good quality company based on its long-term financial performance. The company has achieved a five-year sales compound annual growth rate (CAGR) of 10.63%, though its operating profit growth over the same period has been more modest at 4.83% annually. The average EBIT to interest coverage ratio is a healthy 11.61 times, and the company maintains low leverage with an average net debt to equity ratio of 0.11.
Other quality indicators include no promoter share pledging, a tax ratio of 24.20%, and a dividend payout ratio consistent with its earnings profile. The company’s average return on equity (ROE) is 14.29%, which is considered moderate.
Summary of Financial Trends
The short-term financial trend as of March 2026 is positive, with several key metrics reaching record highs. These include quarterly net sales, operating profit to interest coverage, cash reserves, and profit after tax. Earnings per share (EPS) for the quarter stood at ₹8.13, the highest recorded figure. Interest expenses also reached a quarterly peak of ₹32.69 crores, reflecting increased financing costs.
Granules India Ltd’s journey to this all-time high price has been supported by consistent financial discipline, strong institutional backing, and favourable market dynamics within the pharmaceutical sector. The stock’s performance relative to the broader market and its sector peers highlights its resilience and capacity to generate shareholder value over both short and long-term horizons.
